Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2023 07:00 ET | Source: Immunovant Inc.

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Initial data from the Phase 1 clinical trial of IMVT-1402 on track for September 2023 (single-ascending dose) and October/November 2023 (multiple-ascending dose) Phase 2 proof-of-concept data for...
May 22, 2023 07:00 ET | Source: Immunovant Inc.

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New...
February 03, 2023 07:00 ET | Source: Immunovant Inc.

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in...
November 07, 2022 08:00 ET | Source: Immunovant Inc.

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
November 04, 2022 07:00 ET | Source: Immunovant Inc.

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiledNew development programs for batoclimab in chronic inflammatory...